How much did Formycon achieve in EBIT for the current year?
In the current year, Formycon has achieved an EBIT of -36.29 M EUR.
Formycon EBIT 2025
Formycon EBIT
-36.29 M EUR
Ticker
FYB.DE
ISIN
DE000A1EWVY8
WKN
A1EWVY
In 2025, Formycon's EBIT was -36.29 M EUR, a 54.15% increase from the -23.54 M EUR EBIT recorded in the previous year.
The Formycon EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2030e | - |
| 2029e | 27.11 |
| 2028e | 59.16 |
| 2027e | 7.65 |
| 2026e | -15.41 |
| 2025e | -36.29 |
| 2024 | -23.54 |
| 2023 | -0.37 |
| 2022 | -17.73 |
| 2021 | -14 |
| 2020 | -6.54 |
| 2019 | -2.21 |
| 2018 | 7.19 |
| 2017 | -1.51 |
| 2016 | -3.97 |
| 2015 | 0.7 |
| 2014 | 0.87 |
| 2013 | -7.74 |
| 2012 | -2.46 |
| 2011 | -1.36 |
| 2010 | -1.02 |
Formycon Revenue, EBIT, Net Income DE000A1EWVY8 · A1EWVY
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Formycon, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Formycon from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Formycon’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Formycon. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Formycon’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Formycon’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Formycon’s growth potential.
Formycon Revenue, EBIT and net profit per share
| Date | Formycon Revenue | Formycon EBIT | Formycon Net Income |
|---|---|---|---|
| 2030e | 165.3 M undefined | 0 undefined | 0 undefined |
| 2029e | 133.45 M undefined | 27.11 M undefined | 0 undefined |
| 2028e | 166 M undefined | 59.16 M undefined | 0 undefined |
| 2027e | 141.75 M undefined | 7.65 M undefined | 13.5 M undefined |
| 2026e | 107.8 M undefined | -15.41 M undefined | -5.71 M undefined |
| 2025e | 61.1 M undefined | -36.29 M undefined | -33.64 M undefined |
| 2024 | 69.67 M undefined | -23.54 M undefined | -125.67 M undefined |
| 2023 | 77.7 M undefined | -369,000 undefined | 75.8 M undefined |
| 2022 | 42.5 M undefined | -17.73 M undefined | 35.99 M undefined |
| 2021 | 36.61 M undefined | -14 M undefined | -13.29 M undefined |
| 2020 | 34.3 M undefined | -6.54 M undefined | -6.73 M undefined |
| 2019 | 33.92 M undefined | -2.21 M undefined | -2.29 M undefined |
| 2018 | 43.18 M undefined | 7.19 M undefined | 7.1 M undefined |
| 2017 | 29.11 M undefined | -1.51 M undefined | -1.58 M undefined |
| 2016 | 19.66 M undefined | -3.97 M undefined | -4.07 M undefined |
| 2015 | 17.15 M undefined | 696,500 undefined | 577,500 undefined |
| 2014 | 12.67 M undefined | 873,300 undefined | 860,300 undefined |
| 2013 | 410,000 undefined | -7.74 M undefined | -7.74 M undefined |
| 2012 | 550,000 undefined | -2.46 M undefined | -2.4 M undefined |
| 2011 | 100,000 undefined | -1.36 M undefined | -1.29 M undefined |
| 2010 | 50,000 undefined | -1.02 M undefined | -1.01 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2010 | 50,000 EUR | -1.02 M EUR | -1.01 M EUR |
| 2011 | 100,000 EUR | -1.36 M EUR | -1.29 M EUR |
| 2012 | 550,000 EUR | -2.46 M EUR | -2.4 M EUR |
| 2013 | 410,000 EUR | -7.74 M EUR | -7.74 M EUR |
| 2014 | 12.67 M EUR | 873,300 EUR | 860,300 EUR |
| 2015 | 17.15 M EUR | 696,500 EUR | 577,500 EUR |
| 2016 | 19.66 M EUR | -3.97 M EUR | -4.07 M EUR |
| 2017 | 29.11 M EUR | -1.51 M EUR | -1.58 M EUR |
| 2018 | 43.18 M EUR | 7.19 M EUR | 7.1 M EUR |
| 2019 | 33.92 M EUR | -2.21 M EUR | -2.29 M EUR |
| 2020 | 34.3 M EUR | -6.54 M EUR | -6.73 M EUR |
| 2021 | 36.61 M EUR | -14 M EUR | -13.29 M EUR |
| 2022 | 42.5 M EUR | -17.73 M EUR | 35.99 M EUR |
| 2023 | 77.7 M EUR | -369,000 EUR | 75.8 M EUR |
| 2024 | 69.67 M EUR | -23.54 M EUR | -125.67 M EUR |
| 2025e | 61.1 M EUR | -36.29 M EUR | -33.64 M EUR |
| 2026e | 107.8 M EUR | -15.41 M EUR | -5.71 M EUR |
| 2027e | 141.75 M EUR | 7.65 M EUR | 13.5 M EUR |
| 2028e | 166 M EUR | 59.16 M EUR | 0 EUR |
| 2029e | 133.45 M EUR | 27.11 M EUR | 0 EUR |
| 2030e | 165.3 M EUR | 0 EUR | 0 EUR |
Formycon stock margins DE000A1EWVY8 · A1EWVY
The Formycon margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Formycon. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Formycon.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Formycon's sales revenue. A higher gross margin percentage indicates that the Formycon retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Formycon's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Formycon's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Formycon's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Formycon. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Formycon's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Formycon Margin History
| Formycon Gross margin | Formycon Profit margin | Formycon EBIT margin | Formycon Profit margin |
|---|---|---|---|
| 2030e | 20.25 % | 0 % | 0 % |
| 2029e | 20.25 % | 20.31 % | 0 % |
| 2028e | 20.25 % | 35.64 % | 0 % |
| 2027e | 20.25 % | 5.4 % | 9.52 % |
| 2026e | 20.25 % | -14.29 % | -5.3 % |
| 2025e | 20.25 % | -59.4 % | -55.06 % |
| 2024 | 20.25 % | -33.79 % | -180.37 % |
| 2023 | 29.49 % | -0.47 % | 97.55 % |
| 2022 | 28.41 % | -41.72 % | 84.69 % |
| 2021 | 26.96 % | -38.24 % | -36.3 % |
| 2020 | 22.25 % | -19.07 % | -19.62 % |
| 2019 | 34.59 % | -6.52 % | -6.76 % |
| 2018 | 43.79 % | 16.65 % | 16.44 % |
| 2017 | 28.73 % | -5.2 % | -5.43 % |
| 2016 | 21.75 % | -20.21 % | -20.68 % |
| 2015 | 48.23 % | 4.06 % | 3.37 % |
| 2014 | 53.37 % | 6.89 % | 6.79 % |
| 2013 | -263.41 % | -1,887.8 % | -1,887.8 % |
| 2012 | 85.45 % | -447.27 % | -436.36 % |
| 2011 | 70 % | -1,360 % | -1,290 % |
| 2010 | 80 % | -2,040 % | -2,020 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2010 | 80 % | -2,040 % | -2,020 % |
| 2011 | 70 % | -1,360 % | -1,290 % |
| 2012 | 85.45 % | -447.27 % | -436.36 % |
| 2013 | -263.41 % | -1,887.8 % | -1,887.8 % |
| 2014 | 53.37 % | 6.89 % | 6.79 % |
| 2015 | 48.23 % | 4.06 % | 3.37 % |
| 2016 | 21.75 % | -20.21 % | -20.68 % |
| 2017 | 28.73 % | -5.2 % | -5.43 % |
| 2018 | 43.79 % | 16.65 % | 16.44 % |
| 2019 | 34.59 % | -6.52 % | -6.76 % |
| 2020 | 22.25 % | -19.07 % | -19.62 % |
| 2021 | 26.96 % | -38.24 % | -36.3 % |
| 2022 | 28.41 % | -41.72 % | 84.69 % |
| 2023 | 29.49 % | -0.47 % | 97.55 % |
| 2024 | 20.25 % | -33.79 % | -180.37 % |
| 2025e | 20.25 % | -59.4 % | -55.06 % |
| 2026e | 20.25 % | -14.29 % | -5.3 % |
| 2027e | 20.25 % | 5.4 % | 9.52 % |
| 2028e | 20.25 % | 35.64 % | 0 % |
| 2029e | 20.25 % | 20.31 % | 0 % |
| 2030e | 20.25 % | 0 % | 0 % |
Formycon Aktienanalyse
What does Formycon do?
Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Formycon's EBIT
Formycon's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Formycon's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Formycon's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Formycon’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Formycon stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Formycon.
How has the EBIT of Formycon developed in recent years?
The EBIT of Formycon has increased by 54.155% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Formycon?
The EBIT of Formycon is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Formycon pay?
Over the past 12 months, Formycon paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Formycon is expected to pay a dividend of 0 EUR.
What is the dividend yield of Formycon?
The current dividend yield of Formycon is .
When does Formycon pay dividends?
Formycon pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Formycon?
Formycon paid dividends every year for the past 0 years.
What is the dividend of Formycon?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Formycon located?
Formycon is assigned to the 'Health' sector.
Wann musste ich die Aktien von Formycon kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Formycon from 7/9/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/9/2025.
When did Formycon pay the last dividend?
The last dividend was paid out on 7/9/2025.
What was the dividend of Formycon in the year 2024?
In the year 2024, Formycon distributed 0 EUR as dividends.
In which currency does Formycon pay out the dividend?
The dividends of Formycon are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Formycon stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Formycon
Our stock analysis for Formycon Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Formycon Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
